A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary

Site
Hackensack

Sponsor
Aveo

Protocol Number
AV-951-15-303

To Learn More Call
201-510-0910